黑料网官网

Tianjin Xingchuan Biotechnology Limited Company specializes in biotechnology and is known for its research and development activities, particularly in the field of drug discovery and therapeutic innovations. Founded in 2021, the company is involved in the development of CAR-NK (Chimeric Antigen Receptor Natural Killer) immune cell therapy, which is aimed at treating various types of cancers including lung, liver, bowel cancers, and B lymphoma. CAR-NK therapy is designed to be cost-effective and scalable, providing a more affordable alternative to CAR-T cell therapy. Xingchuan Biotechnology is a private venture-backed company with notable funding from investors such as ChosenMed and Rongyu Capital. Their focus on immunotherapy and cancer treatments highlights their commitment to addressing critical medical challenges.